<DOC>
	<DOCNO>NCT02153424</DOCNO>
	<brief_summary>The primary objective study identify describe suspect ( AEs ) patient NVAF treat Apixaban , request National Center Pharmacovigilance ( CNFV ) Mexico .</brief_summary>
	<brief_title>Early Post-marketing Study Eliquis ( Apixaban )</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com All patient NVAF sentinel site CNFV Mexico receive least 1 dose Apixaban reduce risk stroke systemic embolism specify 24month study period Subjects receive Apixaban part clinical trial Subjects receive Apixaban indication local approval ( ie , reduce risk stroke systemic embolism patient NVAF )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>